Health
Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference
BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chairman, President and Chief Executive Officer, will participate in a fireside chat at the upcoming Bank of America Global Healthcare Conference on Wednesday, May 13 at 3:00 p.m. PT in Las Vegas. The fireside chat will be webcasted
About this update from Rhythm Pharmaceuticals, Inc.
[{"type":"image","alt":"Rhythm Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Rhythm Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":105,"url":"https://media.zenfs.com/en/globenewswire.com/6c26dd8fa407cbf7aa92759a8a5fb54c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/diOYkE69oi1YPSL0HU1OAw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0Nw--/https://media.zenfs.com/en/globenewswire.com/6c26dd8fa407cbf7aa92759a8a5fb54c","width":300,"height":105},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/diOYkE69oi1YPSL0HU1OAw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0Nw--/https://media.zenfs.com/en/globenewswire.com/6c26dd8fa407cbf7aa92759a8a5fb54c","width":300,"height":105}},"lazy":false},{"type":"text","content":"BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chairman, President and Chief Executive Officer, will participate in a fireside chat at the upcoming Bank of America Global Healthcare Conference on Wednesday, May 13 at 3:00 p.m. PT in Las Vegas.","length":463,"tagName":"p"},{"type":"text","content":"The fireside chat will be webcasted and available under “Events & Presentations” in the Investor Relations section of the Company’s website at www.rhythmtx.com. A replay of the webcast will be available on the Rhythm website for 30 days following the presentation.","length":273,"tagName":"p"},{"type":"text","content":"About Rhythm Pharmaceuticals Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with rare neuroendocrine diseases. Rhythm’s lead asset, IMCIVREE® (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the U.S. Food and Drug Administration (FDA) to reduce excess body weight and maintain weight reduction long term in adult and pediatric patients aged 4 years and older with acquired hypothalamic obesity, adult and pediatric patients 2 years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin typ...